AusperBio Completes Patient Enrollment in Phase III AUSHINE Study of AHB-137 for Chronic Hepatitis B
SAN FRANCISCO, Dec. 22, 2025 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company developing targeted ...
SAN FRANCISCO, Dec. 12, 2025 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company developing oligonucleotide-based ...
Pooled 48-week results from two Phase II studies show sustained antiviral responses and a favorable safety profile of AHB-137 in HBeAg-negative chronic hepatitis B patients on NA therapy. The ...
In a statement, PHB said that including the interim income distribution of 2.50 sen per unit declared in April 2025, AHB’s total income distribution for the financial year 2025 (FY2025) amounts to ...
#1059 adds a dependency on config_defines.svh in ahb_lite_address_decoder.sv without adding an include. This makes the compile order more important and makes it so that some tools (such as Vivado) may ...
AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a clinical-stage biotechnology company advancing targeted oligonucleotide therapies for chronic hepatitis B (CHB) ...
SAN FRANCISCO, Sept. 18, 2025 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a clinical-stage biotechnology company advancing targeted ...
A new brain-computer interface can decode a person's inner speech, which could help people with paralysis communicate. When you purchase through links on our site, we may earn an affiliate commission.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback